Please login first
John Stergiou  - - - 
Top co-authors
Anna Potamianou

51 shared publications

Aristides Polyzos

3 shared publications

Efthimios Tagaris

2 shared publications

Publication Record
Distribution of Articles published per year 

Total number of journals
published in
Conference 2 Reads 0 Citations Sensitivity Analysis of Climate Change Projection to the Grid Size Resolution over Mediterranean John Stergiou, Efthimios Tagaris, Rafaella - Eleni Sotiropou... Published: 15 July 2016
The 1st International Electronic Conference on Atmospheric Sciences, doi: 10.3390/ecas2016-d002
DOI See at publisher website
Article 0 Reads 1 Citation Phase I trial of weekly docetaxel with a 4-weekly cisplatin administration in patients with advanced gastric carcinoma. Aristides Polyzos, Konstantinos Syrigos, John Stergiou, Chri... Published: 20 January 2005
Cancer Chemotherapy and Pharmacology, doi: 10.1007/s00280-004-0912-0
DOI See at publisher website
PubMed View at PubMed
ABS Show/hide abstract
The docetaxel-cisplatin combination is active against several tumors including gastric cancer but it is followed by severe myelosuppression. Recent experience with weekly taxanes has demonstrated a mild myelotoxicity with high dose intensity. We investigated in a phase I study a weekly schedule of docetaxel on days 1, 8 and 15 and cisplatin on day 1 every 4 weeks in 19 patients with advanced gastric cancer with no prior chemotherapy. Cohorts of patients were treated with escalating doses of docetaxel (starting dose 30 mg/m(2) per week and increments of 10 mg/m(2) per week) and cisplatin (starting dose 70 mg/m(2) and increments of 5 mg/m(2)). Febrile neutropenia was the only dose-limiting event occurring in four (20%) patients; the dose-limiting toxicity was reached at dose level three (docetaxel 40 mg/m(2) per week and cisplatin 75 mg/m(2)). The maximum-tolerated dose was 40 mg/m(2) per week for docetaxel and 70 mg/m(2) every 4 weeks for cisplatin. Grade 3/4 neutropenia occurred in six patients (30%); early death occurred in one patient with septic shock because of neutropenia and another with acute coronary ischemia. Two (11%) complete and two (11%) partial responses were documented (ORR 22%; 95% CI 3-39%), with a median response duration of 5 months and median time to progression of 7 months. In conclusion, the combination of weekly docetaxel plus cisplatin is feasible with moderate toxicity and merits further investigation in phase II studies in advanced gastric cancer.